...
首页> 外文期刊>Internal medicine. >Effects of Immunosuppressive Therapy in a Patient with Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria (AA-PNH) Syndrome during Ongoing Eculizumab Treatment
【24h】

Effects of Immunosuppressive Therapy in a Patient with Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria (AA-PNH) Syndrome during Ongoing Eculizumab Treatment

机译:持续的依库丽单抗治疗期间再生障碍性贫血-阵发性夜间血红蛋白尿(AA-PNH)综合征患者的免疫抑制治疗的效果。

获取原文
获取原文并翻译 | 示例
           

摘要

A 65-year-old woman experienced a hemolytic attack triggered by sepsis. She presented with markedly increased CD55-CD59-erythrocytes and the signs of bone marrow failure, which led to a diagnosis of aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome. There was a possibility of increasing hemolysis, as large PNH clones remained after immunosuppressive therapy (IST). Accordingly, eculizumab was first used to control the hemolytic attack followed by IST with antithymocyte globulin and cyclosporine A. The patient was successfully weaned from blood transfusions and has been followed up without any recurrence of hemolytic attacks.
机译:一名65岁的妇女经历了由败血症引发的溶血性发作。她表现出明显增加的CD55-CD59-红细胞和骨髓衰竭的体征,从而导致了再生障碍性贫血-阵发性夜间血红蛋白尿(AA-PNH)综合征的诊断。免疫抑制治疗(IST)后仍有大量PNH克隆残留,有可能增加溶血。因此,首先使用依库丽单抗来控制溶血性发作,其次是使用抗胸腺细胞球蛋白和环孢素A进行IST治疗。该患者已成功地从输血中撤离,并且得到了随访,没有任何溶血性发作复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号